L-Nin 400mg Injection contains Teicoplanin, a glycopeptide antibiotic effective against a broad spectrum of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and Enterococci species. It is primarily indicated for the treatment of serious infections such as bacteremia, endocarditis, bone and joint infections, skin and soft tissue infections, and respiratory tract infections caused by susceptible organisms. Teicoplanin exerts its antibacterial effect by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. The injection is administered intravenously or intramuscularly, with dosing individualized based on the severity of infection, patient weight, and renal function. L-Nin 400mg Injection offers a favorable pharmacokinetic profile characterized by a prolonged half-life, allowing for once-daily dosing in most cases, thereby improving patient compliance. It is essential to monitor renal function during therapy, as dose adjustments may be necessary in patients with impaired renal clearance. Common adverse effects include hypersensitivity reactions, nephrotoxicity, and local injection site reactions. L-Nin 400mg Injection should be used under strict medical supervision, with susceptibility testing recommended to ensure appropriate use and minimize the development of resistance. This product is contraindicated in patients with known hypersensitivity to Teicoplanin or other glycopeptides.